Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer

被引:55
作者
Cortejoso, Lucia [1 ]
Garcia, Maria I. [1 ]
Garcia-Alfonso, Pilar [2 ]
Gonzalez-Haba, Eva [1 ]
Escolar, Fernando [1 ]
Sanjurjo, Maria [1 ]
Lopez-Fernandez, Luis A. [1 ]
机构
[1] Hosp Gen Univ Gregorio Maranon, Serv Farm, Inst Invest Sanitaria Gregorio Maranon, Madrid 28007, Spain
[2] Hosp Gen Univ Gregorio Maranon, Med Oncol Serv, Inst Invest Sanitaria Gregorio Maranon, Madrid 28007, Spain
关键词
Toxicity; Pharmacogenetics; Irinotecan; Oxaliplatin; Colorectal cancer; SINGLE NUCLEOTIDE POLYMORPHISMS; UGT1A1-ASTERISK-28; GENOTYPE; GENETIC-VARIANTS; GASTROINTESTINAL TOXICITY; 1ST-LINE TREATMENT; P-GLYCOPROTEIN; EXPRESSION; PREDICTS; FLUOROURACIL; NEUTROPENIA;
D O I
10.1007/s00280-013-2145-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Oxaliplatin or irinotecan is usually administered jointly with fluoropyrimidines in colorectal cancer patients treated with chemotherapy. Both drugs have different toxicity patterns. Biomarkers for predicting high-risk severe adverse reactions can help select the best treatment. A retrospective analysis of 106 colorectal cancer patients receiving an oxaliplatin-based treatment and 56 receiving an irinotecan-based treatment was performed. One copy number variant (GSTT1) and nine polymorphisms in irinotecan and oxaliplatin metabolism, transport or DNA repair genes (ABCB1, UGT1A1, XRCC1, ERCC1, ERCC2, GSTP1) were genotyped by SNaPshot, polymerase chain reactions' length fragments, or copy number assays. In irinotecan-treated patients, C allele of ABCB1 C1236T SNP was associated with a lower risk of asthenia (OR = 0.043; 96 % CI = 0.004-0.444; P = 0.008) and C allele of ABCB1 C3435T SNP was associated with a lower risk of diarrhea (OR = 0.162; 95 % CI = 0.031-0.844; P = 0.031); and individuals with two copies of GSTT1 gene had a lower risk for asthenia (OR = 0.074; 95 % CI = 0.009-0.617; P = 0.016). In oxaliplatin-treated patients, carriers of two C variants of Asn118Asn ERCC1 SNP had a lower risk for neutropenia (OR = 0.203; 95 % CI = 0.060-0.683; P = 0.01). These biomarkers could help oncologists select the best treatment by reducing toxicity associated with irinotecan or oxaliplatin in colorectal cancer patients, thus increasing their quality of life.
引用
收藏
页码:1463 / 1472
页数:10
相关论文
共 60 条
[1]
The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens [J].
Artac, Mehmet ;
Bozcuk, Hakan ;
Pehlivan, Sacide ;
Akcan, Songuel ;
Pehlivan, Mustafa ;
Sever, Tugce ;
Ozdogan, Mustafa ;
Savas, Burhan .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (06) :803-809
[2]
UGT1A1*20 and other UGT1A polymorphisms as determinants of irinotecan toxicity [J].
Biason, P. ;
Masier, S. ;
Toffoli, G. .
JOURNAL OF CHEMOTHERAPY, 2008, 20 (02) :158-165
[3]
Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05 [J].
Boige, Valerie ;
Mendiboure, Jean ;
Pignon, Jean-Pierre ;
Loriot, Marie-Anne ;
Castaing, Marine ;
Barrois, Michel ;
Malka, David ;
Tregouet, David-Alexandre ;
Bouche, Olivier ;
Le Corre, Delphine ;
Miran, Isabelle ;
Mulot, Claire ;
Ducreux, Michel ;
Beaune, Philippe ;
Laurent-Puig, Pierre .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15) :2556-2564
[4]
Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial [J].
Braun, Michael S. ;
Richman, Susan D. ;
Thompson, Lindsay ;
Daly, Catherine L. ;
Meade, Angela M. ;
Adlard, Julian W. ;
Allan, James M. ;
Parmar, Mahesh K. B. ;
Quirke, Philip ;
Seymour, Matthew T. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) :5519-5528
[5]
Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan [J].
Cecchin, Erika ;
Innocenti, Federico ;
D'Andrea, Mario ;
Corona, Giuseppe ;
De Mattia, Elena ;
Biason, Paola ;
Buonadonna, Angela ;
Toffoli, Giuseppe .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) :2457-2465
[6]
Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma [J].
Chen, Yen-Chung ;
Tzeng, Cheng-Hwai ;
Chen, Po-Min ;
Lin, Jen-Kou ;
Lin, Tzu-Chen ;
Chen, Wei-Shone ;
Jiang, Jeng-Kae ;
Wang, Huann-Sheng ;
Wang, Wei-Shu .
CANCER SCIENCE, 2010, 101 (02) :530-535
[7]
Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer [J].
Chua, W. ;
Goldstein, D. ;
Lee, C. K. ;
Dhillon, H. ;
Michael, M. ;
Mitchell, P. ;
Clarke, S. J. ;
Iacopetta, B. .
BRITISH JOURNAL OF CANCER, 2009, 101 (06) :998-1004
[8]
Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer [J].
Chua, Wei ;
Kho, Patricia S. ;
Moore, Melissa M. ;
Charles, Kellie A. ;
Clarke, Stephen J. .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 79 (03) :224-250
[9]
Cortejoso L, 2012, PHARMACOGENOMICS, V13, P1173, DOI [10.2217/PGS.12.95, 10.2217/pgs.12.95]
[10]
UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan [J].
Cote, Jean-Francois ;
Kirzin, Sylvain ;
Krarnar, Andrew ;
Mosnier, Jean-Francois ;
Diebold, Marie-Daniele ;
Soubeyran, Isabelle ;
Thirouard, Anne-Sophie ;
Selves, Janick ;
Laurent-Puig, Pierre ;
Ychou, Marc .
CLINICAL CANCER RESEARCH, 2007, 13 (11) :3269-3275